Salmon fibrin glue in rats: Antibody studies

Biologicals

Volumn 40, Issue 1, 2012, Pages 55-60

  Laidmäe, Ivo ^a,b   Belozjorova, Jevgenia ^a   Sawyer, Evelyn S ^c   Janmey, Paul A ^d   Uibo, Raivo ^a,b  

^a UNIVERSITY OF TARTU   (Estonia)

^b University of Tartu ^*  (Estonia)

^c Sea Run Holdings Inc   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antibodies; Fibrinogen; Immunological crossreactivity; Rats; Thrombin

Indexed keywords

FIBRIN GLUE; FIBRINOGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; THROMBIN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; CROSS REACTION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; SALMON; THROMBIN TIME;

ANIMALS; CATTLE; DRUG EVALUATION, PRECLINICAL; FIBRIN TISSUE ADHESIVE; FISH PROTEINS; HUMANS; IMMUNOGLOBULIN G; MODELS, BIOLOGICAL; RATS; SALMON;

ANIMALIA; BOVINAE; MAMMALIA; RATTUS; SALMO SALAR;

EID: 84856426562     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2011.12.008     Document Type: Article

References (29)

1. Kessler C.M., Ortel T.L. Recent developments in topical thrombins. Thromb Haemost 2009, 102:15-24.
2. Michaud S.E., Wang L.Z., Korde N., Bucki R., Randhawa P.K., Pastore J.J., et al. Purification of salmon thrombin and its potential as an alternative to mammalian thrombins in fibrin sealants. Thromb Res 2002, 107:245-254.
3. Wang L.Z., Gorlin J., Michaud S.E., Janmey P.A., Goddeau R.P., Kuuse R., et al. Purification of salmon clotting factors and their use as tissue sealants. Thromb Res 2000, 100:537-548.
4. Laidmae I., McCormick M.E., Herod J.L., Pastore J.J., Salum T., Sawyer E.S., et al. Stability, sterility, coagulation, and immunologic studies of salmon coagulation proteins with potential use for mammalian wound healing and cell engineering. Biomaterials 2006, 27:5771-5779.
5. Laidmae I., Salum T., Sawyer E.S., Janmey P.A., Uibo R. Characterization of the biological effect of fish fibrin glue in experiments on rats: immunological and coagulation studies. JBiomed Mater Res A 2010, 93:29-36.
6. Lew W.K., Weaver F.A. Clinical use of topical thrombin as a surgical hemostat. Biologics 2008, 2:593-599.
7. Ness P., Creer M., Rodgers G.M., Naoum J.J., Renkens K., Voils S.A., et al. Building an immune-mediated coagulopathy consensus: early recognition and evaluation to enhance post-surgical patient safety. Patient Saf Surg 2009, 3:8.
8. Spotnitz W.D., Burks S. State-of-the-art review: hemostats, sealants, and adhesives II: update as well as how and when to use the components of the surgical toolbox. Clin Appl Thromb Hemost 2010, 16:497-514.
9. Crow S.S., Sullivan V.V., Aysola A.E., Key N.S., Harker-Murray P., Foker J.E., et al. Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin. Ann Thorac Surg 2007, 83:1547-1549.
10. Kajitani M., Ozdemir A., Aguinaga M., Jazieh A.R., Flick J.T., Antakli T. Severe hemorrhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product. JCard Surg 2000, 15:378-382.
11. Lawson J.H. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost 2006, 32(Suppl. 1):98-110.
12. Lawson J.H., Lynn K.A., Vanmatre R.M., Domzalski T., Klemp K.F., Ortel T.L., et al. Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg 2005, 79:1037-1038.
13. Lawson J.H., Pennell B.J., Olson J.D., Mann K.G. Isolation and characterization of an acquired antithrombin antibody. Blood 1990, 76:2249-2257.
14. Sarfati M.R., Dilorenzo D.J., Kraiss L.W., Galt S.W. Severe coagulopathy following intraoperative use of topical thrombin. Ann Vasc Surg 2004, 18:349-351.
15. Streiff M.B., Ness P.M. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 2002, 42:18-26.
16. Rothwell S.W., Settle T., Wallace S., Dorsey J., Simpson D., Bowman J.R., et al. The long term immunological response of swine after two exposures to a salmon thrombin and fibrinogen hemostatic bandage. Biologicals 2010, 38:619-628.
17. Chapman W.C., Singla N., Genyk Y., McNeil J.W., Renkens K.L., Reynolds T.C., et al. Aphase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. JAm Coll Surg 2007, 205:256-265.
18. Carroll J.F., Moskowitz K.A., Edwards N.M., Hickey T.J., Rose E.A., Budzynski A.Z. Immunologic assessment of patients treated with bovine fibrin as a hemostatic agent. Thromb Haemost 1996, 76:925-931.
19. Fastenau D.R., McIntyre J.A. Immunochemical analysis of polyspecific antibodies in patients exposed to bovine fibrin sealant. Ann Thorac Surg 2000, 69:1867-1872.
20. Spotnitz W.D., Burks S. Hemostats, sealants, and adhesives: components of the surgical toolbox. Transfusion 2008, 48:1502-1516.
21. Racine R., Winslow G.M. IgM in microbial infections: taken for granted?. Immunol Lett 2009, 125:79-85.
22. Schwartz-Albiez R., Monteiro R.C., Rodriguez M., Binder C.J., Shoenfeld Y. Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation. Clin Exp Immunol 2009, 158(Suppl. 1):43-50.
23. R Development Core Team R: a language and environment for statistical computing 2007, R Foundation for Statistical Computing, Vienna, Austria.
24. Rothwell S.W., Sawyer E., Dorsey J., Flournoy W.S., Settle T., Simpson D., et al. Wound healing and the immune response in swine treated with a hemostatic bandage composed of salmon thrombin and fibrinogen. JMater Sci Mater Med 2009, 20:2155-2166.
25. Singla N.K., Ballard J.L., Moneta G., Randleman C.D., Renkens K.L., Alexander W.A. Aphase 3b, open-label, single-group immunogenicity and safety study of topical recombinant thrombin in surgical hemostasis. JAm Coll Surg 2009, 209:68-74.
26. Ortel T.L., Mercer M.C., Thames E.H., Moore K.D., Lawson J.H. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001, 233:88-96.
27. Lin W.S., Chen P.C., Yang C.D., Cho E., Hahn B.H., Grossman J., et al. Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum 2007, 56:1638-1647.
28. Wegner N., Lundberg K., Kinloch A., Fisher B., Malmstrom V., Feldmann M., et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev 2010, 233:34-54.
29. Yang Y.H., Hwang K.K., FitzGerald J., Grossman J.M., Taylor M., Hahn B.H., et al. Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin. JImmunol 2006, 177:8219-8225.